GlassScriptPhysician profile
J David M Cameron
NPI 1447206875
$3,504.04
in general payments reported to CMS, 2019-2025
26 companies · $1,748 in 2025
The $1,748 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $265 · 2024: $1,490 · 2025: $1,748.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,504.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,504.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $685.07 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Mayne Pharma Commercial LLC | $632.67 | 2023-2025 | |
| Abbvie INC. | $572.97 | 2023-2025 | Ubrelvy, Qulipta, Creon |
| Dexcom, INC. | $280.46 | 2024-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $251.57 | 2024-2025 | Airsupra, Breztri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $109.64 | 2024-2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $95.05 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $94.89 | 2024-2025 | Spravato |
| Exact Sciences Corporation | $92.69 | 2024-2025 | Cologuard Collection Kit |
| Bausch Health US, LLC | $74.00 | 2024 | Aplenzin |
| Lilly USA, LLC | $66.65 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Tris Pharma INC | $61.98 | 2024-2025 | Dyanavel Xr |
| Xeris Pharmaceuticals, INC. | $61.66 | 2024-2025 | Gvoke Hypopen |
| Abbott Laboratories | $58.25 | 2025 | Freestyle Libre 3 |
| Edwards Lifesciences Corporation | $51.90 | 2024-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $50.55 | 2024-2025 | Trintellix |
| Glaxosmithkline, LLC. | $47.81 | 2023-2025 | Arexvy, Shingrix |
| Hologic Sales and Service, LLC | $30.58 | 2025 | Thinprep 2000 Processor, Aptima |
| Kowa Pharmaceuticals America, INC. | $28.60 | 2024 | Zoryve |
| Axsome Therapeutics, INC. | $26.32 | 2025 | Auvelity |
| Medtronic, INC. | $26.29 | 2025 | Venaseal |
| Seqirus USA INC | $24.85 | 2024 | Flucelvax, Fluad |
| Phadia US INC. | $22.99 | 2024 | Immunocap |
| Phathom Pharmaceuticals, INC. | $22.05 | 2024 | Voquezna |
| Amgen INC. | $18.00 | 2025 | Repatha |
| Pfizer INC. | $16.55 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw J David Cameron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.